543 related articles for article (PubMed ID: 15278097)
1. Glutamate as a therapeutic target in psychiatric disorders.
Javitt DC
Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
Heresco-Levy U
Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
[TBL] [Abstract][Full Text] [Related]
3. Glycine modulators in schizophrenia.
Javitt DC
Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
[TBL] [Abstract][Full Text] [Related]
4. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
5. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
Heresco-Levy U
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
[TBL] [Abstract][Full Text] [Related]
6. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
7. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Tsai G; Lane HY; Yang P; Chong MY; Lange N
Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
[TBL] [Abstract][Full Text] [Related]
8. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.
Krystal JH; D'Souza DC; Petrakis IL; Belger A; Berman RM; Charney DS; Abi-Saab W; Madonick S
Harv Rev Psychiatry; 1999; 7(3):125-43. PubMed ID: 10483932
[TBL] [Abstract][Full Text] [Related]
9. Glutamate receptor ligands as anxiolytics.
Chojnacka-Wójcik E; Kłodzinska A; Pilc A
Curr Opin Investig Drugs; 2001 Aug; 2(8):1112-9. PubMed ID: 11892923
[TBL] [Abstract][Full Text] [Related]
10. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
Hashimoto K; Iyo M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
[TBL] [Abstract][Full Text] [Related]
11. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.
Ritzén A; Mathiesen JM; Thomsen C
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):202-13. PubMed ID: 16176554
[TBL] [Abstract][Full Text] [Related]
12. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
Yang CR; Svensson KA
Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
[TBL] [Abstract][Full Text] [Related]
13. The NMDA receptor complex: a long and winding road to therapeutics.
Wood PL
IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
[TBL] [Abstract][Full Text] [Related]
14. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T; Mouri A; Murai R; Noda Y
Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
[TBL] [Abstract][Full Text] [Related]
15. Glutamate transporters and metabotropic receptors regulate excitatory neurotransmission in the medial entorhinal cortex of the rat.
Iserhot C; Gebhardt C; Schmitz D; Heinemann U
Brain Res; 2004 Nov; 1027(1-2):151-60. PubMed ID: 15494166
[TBL] [Abstract][Full Text] [Related]
16. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
Javitt DC
Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
[TBL] [Abstract][Full Text] [Related]
17. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
18. Biological perspectives: the role of glutamate in schizophrenia and its treatment.
Steele D; Moore RL; Swan NA; Grant JS; Keltner NL
Perspect Psychiatr Care; 2012 Jul; 48(3):125-8. PubMed ID: 22724397
[TBL] [Abstract][Full Text] [Related]
19. [Glycine therapy of schizophrenia; its rationale and a review of clinical trials].
Semba J
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):71-80. PubMed ID: 9800198
[TBL] [Abstract][Full Text] [Related]
20. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
